05/02/2010 - Le dernier des Robinson suisses ?

Lorsque Daniel Vasella a annoncé son départ de la direction opérationnelle de Novartis, ce fut un véritable coup de tonnerre dans les ambiances feutrées suisses.... (n°449, Le Billet Bio de H. ELLA, page 2)

18/01/2010 - 2010 : le come back des financements early-stage ?

Risk is beautiful ! Voilà une phrase qui n’était plus guère en vogue depuis plusieurs mois et qui semble reprendre de la vigueur. Les prédicateurs de la reprise sont là... (n°446, Dernière heure, page 0)

21/09/2009 - Ophtalmologie : Alcon s'offre ESBATech AG pour 400 M€

(n°431, Repères, page 4)

10/03/2008 Alcon Announces Leadership Change to Research and Development Organization

... Alcon, Inc. (NYSE:ACL) announced today that Gerald D. Cagle, Ph.D., Alcon's senior vice president of Research and Development and chief scientific officer, will ...

07/03/2008 Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma

... Alcon, Inc. (NYSE: ACL) released today the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate ad ...

07/02/2008 Alcon's Fourth Quarter Sales Rise 20.0 Percent

... Alcon, Inc. (NYSE:ACL) reported global sales of $1,469.7 million for the fourth quarter of 2007, an increase of 20.0 percent over global sales for the fourth qu ...

24/09/2007 Alcon Receives FDA Decision on RETAANE(R) Suspension for Wet AMD

... Alcon, Inc. (NYSE:ACL) announced today that the company received an approvable letter from the United States Food and Drug Administration (FDA) for RETAANE(R) 1 ...

31/07/2007 Alcon's Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ(TM) Solution, Approved in Japan

... Alcon, Inc. (NYSE: ACL) announced today that the Ministry of Health, Labor and Welfare in Japan has approved TRAVATANZ(TM) (travoprost ophthalmic solution) 0.00 ...

18/07/2007 Anecortave Acetate Clinical Trial Data for Glaucoma Presented at World Congress of Glaucoma

... Alcon, Inc. (NYSE: ACL) released today the three-month interim results of the first controlled clinical study of anecortave acetate administered as an anterior ...

18/09/2006 Alcon Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections from NovaCal

... Alcon, Inc. (NYSE:ACL) announced today that one of its affiliates has signed a collaboration and license agreement with NovaCal Pharmaceuticals, Inc. ("NovaCal" ...

26/07/2006 Alcon's Eye Allergy Drug, PATANOL(R) Ophthalmic Solution, Approved in Japan

... Alcon, Inc. (ACL) announced today that it has received approval from the Ministry of Health, Labor and Welfare in Japan to market its eye allergy drug, PATANOL( ...

22/05/2006 AcrySof(R) IQ IOL Designated as a New Technology Intraocular Lens

... Alcon, Inc. (NYSE:ACL) announced today that the Centers for Medicare and Medicaid Services (CMS) recognized the AcrySof(R) IQ intraocular lens (IOL) as belongin ...

24/04/2006 Alcon's First Quarter Sales Rise 8.1 Percent, Net Earnings Increase 18.5 Percent

... Alcon, Inc. (NYSE:ACL) reported global sales of $1,157.1 million for the first quarter of 2006, an increase of 8.1 percent over global sales in the first quar ...